News
A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback